Endocrine Abstracts

Introduction: Daily administration of Pegvisomant normalizes IGF1 levels >71% of acromegalics (1). Few studies have assessed the efficacy of weekly administration. We assessed the efficacy of weekly pegvisomant for 12 months, after withdrawal of long-acting somatostatin analogs (SSA) in acromegalics previously controlled on combination therapy.Design: Fifteen subjects (8 males), age 58 (35–80) (median (range)) years on combination therapy of hig...

Background: It is still uncertain if subclinical thyroid disease or ‘high-normal’ thyroid function are risk-factors for atrial fibrillation (AF).Objectives: To examine the risk of AF in relation to thyroid function.Methods: Patients consulting their general practitioner from 2000–2009 in Copenhagen, Denmark, who underwent thyroid blood tests, were identified by individual-level linkage of nationwide registries. Patie...